FDA Orange Book · active-ingredient family
Finafloxacin
Finafloxacin is approved in 1 FDA application, with therapeutic-equivalence codes, listed patents, and marketing exclusivity from the FDA Orange Book.
Reference-listed drug:XTORO · NDA 206307
1
Brand (NDA)
0
Generics (ANDA)
4
Listed patents
0
Exclusivity periods
Brand (NDA) products · suspension/drops
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| XTORORLD | FONSECA BIOSCIENCES | NDA 206307 | — | Dec 17, 2014 |
Listed patents (4)
| Patent | Expires | In | Type |
|---|---|---|---|
| 9119859 | Jul 02, 2030 | in 4 yr 1 mo | U-1679 |
| 9993483 | Jul 02, 2030 | in 4 yr 1 mo | Product |
| 8536167 | Aug 08, 2031 | in 5 yr 3 mo | U-1679 |
| 9504691 | Nov 21, 2033 | in 7 yr 6 mo | ProductU-1679 |
Finafloxacin — frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.
